Ownership and insider activity for Relmada Therapeutics, Inc. (RLMD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourett...
Price
| Price | $4.22 |
| Market Cap | $443M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Shenouda Maged | P-Purchase | 79,800 | $339K |
| 2026-09-09 | Shenouda Maged | P-Purchase | 120,200 | $505K |
| 2026-09-10 | TRAVERSA SERGIO | P-Purchase | 100,000 | $410K |
| 2026-09-09 | TRAVERSA SERGIO | P-Purchase | 100,000 | $418K |
| 2025-12-15 | TRAVERSA SERGIO | P-Purchase | 27,500 | $113K |
| 2025-12-12 | TRAVERSA SERGIO | A-Award | 1,198,000 | $4.9M |
| 2025-12-12 | Shenouda Maged | A-Award | 828,000 | $3.4M |
| 2025-12-15 | Shenouda Maged | P-Purchase | 11,665 | $48K |
| 2025-12-12 | Ence Chuck | A-Award | 828,000 | $3.4M |
| 2025-12-12 | Fedeli Fabiana | A-Award | 164,000 | $666K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.7M | $2.2M | $9.2M | $36.3M | $2.5M | $44.4M | $5.4M | $4.1M | $3.9M | $3.5M |
| Short-term Investments | 0 | 0 | 0 | $80.2M | $114.6M | $167.5M | $142.9M | $92.2M | $41.1M | $89.5M |
| Receivables | $291916 | $72103 | $247082 | $73091 | $79457 | $86377 | $512432 | 0 | 0 | 0 |
| Inventory | $472500 | $426900 | $459000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.5M | $2.7M | $10.0M | $116.9M | $118.1M | $223.3M | $152.9M | $97.5M | $45.8M | $94.0M |
| Property, Plant & Equipment | $2315 | $12080 | $7210 | $5010 | $1258 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.8M | $3.0M | $10.2M | $117.1M | $118.2M | $223.3M | $152.9M | $97.6M | $45.8M | $94.0M |
| Accounts Payable | $529558 | $765439 | $924359 | $522663 | $8.3M | $11.2M | $5.3M | $3.5M | $4.1M | $1.6M |
| Short-term Debt | $276670 | $285170 | $364204 | $110247 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.4M | $5.9M | $2.6M | $1.5M | $12.6M | $15.1M | $12.5M | $12.2M | $10.3M | $6.4M |
| Long-term Debt | 0 | $2.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.4M | $8.6M | $2.6M | $1.5M | $12.6M | $15.1M | $12.5M | $12.2M | $10.3M | $7.5M |
| Retained Earnings | -$85.4M | -$94.3M | -$111.7M | -$119.9M | -$179.3M | -$305.1M | -$462.1M | -$560.9M | -$640.9M | -$698.3M |
| Total Equity | $1.5M | -$5.5M | $7.6M | $115.7M | $105.6M | $208.3M | $140.4M | $85.4M | $35.5M | $86.5M |
| Total Debt | $276670 | $2.9M | $364204 | $110247 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$1.4M | $702684 | -$8.9M | -$116.3M | -$117.1M | -$211.9M | -$148.3M | -$96.3M | -$44.9M | -$93.0M |
| Working Capital | $1.1M | -$3.2M | $7.4M | $115.5M | $105.5M | $208.2M | $140.4M | $85.3M | $35.5M | $87.6M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 29.52 |
Profitability
| Return on Equity | -47.52% |
| Return on Invested Capital | -30.78% |
| Return on Assets | -28.27% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACET · ACRV · CBUS · FBIO · IMUX · LITS · PMVP
Explore sector: Healthcare · Biotechnology
More sections of RLMD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks